UY26387A1 - PHARMACEUTICALLY ACTIVE COMPOUNDS - Google Patents

PHARMACEUTICALLY ACTIVE COMPOUNDS

Info

Publication number
UY26387A1
UY26387A1 UY26387A UY26387A UY26387A1 UY 26387 A1 UY26387 A1 UY 26387A1 UY 26387 A UY26387 A UY 26387A UY 26387 A UY26387 A UY 26387A UY 26387 A1 UY26387 A1 UY 26387A1
Authority
UY
Uruguay
Prior art keywords
active compounds
pharmaceutically active
pharmaceutically
veterinarily acceptable
compounds
Prior art date
Application number
UY26387A
Other languages
Spanish (es)
Inventor
Mark Edward Bunnage
Keih Michael Devries
Laurence James Harris
Philip Charles Levett
John Paul Mathias
Joanna Teresa Negri
Stephen Derek Albert Street
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to UY26387A priority Critical patent/UY26387A1/en
Publication of UY26387A1 publication Critical patent/UY26387A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de fórmula (I): en la que R1, R2, R4 y R13 son como se han definido, una sal o polimorfo farmacéutica o veterinariamente aceptable de los mismos, o un solvato o profármaco farmacéutica o veterinariamente aceptable de los mismos: son inhibidores potentes y selectivos de la guanosina 3`, 5`- monofosfato cíclico fosfodiesterasa de tipo 5 (GPMc PDE5) y tienen utilidad en el tratamiento de, entre otras afecciones, la disfunción eréctil masculina (MED) y la disfunción sexual femenina (FSD).Compounds of formula (I): wherein R1, R2, R4 and R13 are as defined, a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or prodrug thereof: are potent and selective inhibitors of guanosine 3`, 5` - cyclic monophosphate phosphodiesterase type 5 (GPMc PDE5) and have utility in the treatment of, among other conditions, male erectile dysfunction (MED) and female sexual dysfunction (FSD) .

UY26387A 2000-10-10 2000-10-10 PHARMACEUTICALLY ACTIVE COMPOUNDS UY26387A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY26387A UY26387A1 (en) 2000-10-10 2000-10-10 PHARMACEUTICALLY ACTIVE COMPOUNDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26387A UY26387A1 (en) 2000-10-10 2000-10-10 PHARMACEUTICALLY ACTIVE COMPOUNDS

Publications (1)

Publication Number Publication Date
UY26387A1 true UY26387A1 (en) 2001-06-29

Family

ID=38812252

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26387A UY26387A1 (en) 2000-10-10 2000-10-10 PHARMACEUTICALLY ACTIVE COMPOUNDS

Country Status (1)

Country Link
UY (1) UY26387A1 (en)

Similar Documents

Publication Publication Date Title
CU23198A3 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
TR200003039T2 (en) Pirazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunctions
PE20040197A1 (en) PYRAZOLOPYRIDINES SUBSTITUTED WITH CARBAMATE
WO2002064590A3 (en) Carboline derivatives
WO2002064591A3 (en) Carboline derivatives
WO2002000657A3 (en) Condensed pyrazindione derivatives
NO20015275D0 (en) Unit dosage form
UY28524A1 (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
DE60226970D1 (en) PYRAZINOÄ1 ', 2': 1,6Ü-PYRIDOÄ3,4-BÜ INDOLE-1,4-DION DERIVATIVES
UY26387A1 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
ECSP003703A (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
AP2002002462A0 (en) Pharmaceutically active compounds.
WO2002000656A3 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
HN2000000225A (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
CA2451990A1 (en) A new compound for the treatment of impotence
AR030681A1 (en) PIRAZOLO COMPOUNDS [4,3-] PIRIMIDIN-7-ONAS, PHARMACEUTICAL COMPOSITION, VETERINARY FORMULATION, USE IN THE MANUFACTURE OF MEDICINAL PRODUCT, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, INTERMEDIARY COMPOUNDS AND THEIR PREPARATION
PA8523501A1 (en) CRYSTAL THERAPEUTIC AGENT
MY131573A (en) Use of pde5 inhibitors for the treatment of premature ejaculation
AR028775A1 (en) DERIVATIVES OF PYRIMIDINE AND ITS USE FOR PROFILAXIS AND THERAPY OF CEREBRAL ISCHEMIA
DOP2004000999A (en) TRIAZOL DERIVATIVES REPLACED COO ANTAGONIST OF OXITOCINE
IL165411A0 (en) Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
GT200400187A (en) TRIAZOL DERIVATIVES SUBSTITUTED AS AN OXITOCINE ANTAGONISTS.
HN1999000041A (en) GMPC PDE5 INHIBITING PIRAZOLIPIRIMIDINONES FOR THE TREATMENT OF SEXUAL DYSFECTION

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110715